Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma
NEW YORK, NY / ACCESSWIRE / December 3, 2018 / There was no news to explain the new high that Intec Pharma hit on Friday but Oragenics surged over 30% after announcing the publication of a research paper last week.
The Market Edge Initiates Coverage on:
Oragenics, Inc.
https://marketedgereport.com/report/OGEN/
Intec Pharma Ltd.
https://marketedgereport.com/report/NTEC/
Oragenics, Inc. shares closed up 33.66% on Friday with around 24.7 million shares traded. It was early last week that the company announced the publication of a research paper called "Blueprints for the rational design of therapeutic mutacin 1140 variants." The study focused on structure-activity relationships of the lantibiotic Mutacin 1140 (MU1140) that expand the “drugability†of the MU1140 pipeline. The company is developing a second generation multiple variant of MU1140 called OG716. Dr. Alan Joslyn, Oragenics’ president and CEO stated, “The findings of this study provide insight into a more streamlined and effective development and manufacturing of this new class of anti-infectives. OG716 is targeted for the treatment of C. difficile infections, which have become an increasing health risk worldwide. New drug resistant strains have caused an increase in mortality by more than 400 percent, which are expected to continue to increase until we are able to counter against the resistance. We believe our compound may be an effective treatment for recurrent CDI. In the meantime, we anticipate submitting an Investigational New Drug application with the U.S. Food and Drug Administration to begin clinical development during 2019.â€
Access The Market Edge's Oragenics, Inc.
Research Report:
https://marketedgereport.com/report/OGEN/
Intec Pharma Ltd. shares closed up a little over 17% on Friday with around 1.7 million shares traded. Average trading volume for the stock is only around 177,000 shares. The stock hit a new high of $7.52 despite any significant news from the company. It was in early November that the company announced financial results for the three and nine months ended September 30, 2018 and provided a corporate update. "Throughout the third quarter, we continued to make significant progress across a number of key areas important to advancing our AP platform and for building Intec Pharma into a leading drug delivery company," stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. He added, "We recently reported the completion of enrollment in our pivotal Phase 3 clinical trial of AP-CD/LD, which keeps us on track to report topline data in mid-2019. We remain encouraged by the continued strong participation in our OLE study, which gives us confidence that these data will be available in the second half of 2019 and will provide the long-term safety data required for our regulatory submission. We expect to have data from the PK study of AP-CD/LD 50/500 mg TID by year-end and believe these data will be important as this is a popular dosing regimen in the ACCORDANCE study and having this PK information will be of interest to potential partners and clinicians upon commercial launch.â€
Access The Market Edge's Intec Pharma
Ltd. Research Report:
https://marketedgereport.com/report/NTEC/
Our Actionable Research on Oragenics, Inc. (NYSE: OGEN) and Intec Pharma Ltd. (NASDAQ: NTEC) can be downloaded free of charge at The Market Edge.
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Edge
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
